Interview with Byoung Joo Gwag, CEO, President, Neurotech Pharmaceuticals
What was the vision behind the creation of Neurotech back in 1998, originally as a Research Center, and then as an independent bio-tech company? It all began in 1998 when…
Address: 4F Hyunwoo Building, Gomae- dong 381-1, Giheung-gu, Yongin -si, Gyeonggi-do446-901, Republic of Korea
Tel: 82-31-215-9985
Web: http://gntpharma.com/intro/
Established in 1998 Neurotech Pharmaceuticalshas received the G7 Project Award from the Ministry of Science & Technology:Development of Alzheimer’s Disease models and Neuroprotectant compounds.Neurotech team members are working diligently with shareholder support to develop the next generation of medicines.Neurotech has been developing Neu2000 and AAD-2004 over the last 8 years and has recently discovered two additional promising compounds. Neurotech has also expanded its drug development capabilities over this period. In preparing for competition in the global marketplace, Neurotech has secured sufficient cash flow for R&D Funding through public listing, employing a conservative business model, and establishing a new drug development infrastructure through the introduction of IT. Its partner, Eolith, is a company that specializes in Broadband Convergence Network technology. Neurotech is working with Eolith and large medical center to construct a Ubiquitous Health Monitoring System (UHMS) to select patients with stroke and Alzheimer’s and maximize the efficacy of drugs. Neurotech ultimately seeks to gain entry into the pharmaceutical industry through clinical studies and the marketing of new drugs.In 2008, Neurotech has successfully completed the Neu2000 clinical phase I study in the U.S.
What was the vision behind the creation of Neurotech back in 1998, originally as a Research Center, and then as an independent bio-tech company? It all began in 1998 when…
Could you please introduce Shinpoong, which you founded in 1962, and mention the main milestones of this unique company in the Korean pharmaceutical industry? I founded Shinpoong in a very…
Novartis’ Head Office in Basel, Switzerland as well as several prior international assignments in Asia and Europe. What do you find as the most interesting particularities of the pharmaceutical sector…
Please introduce the Korean Food and Drug Administration (KFDA) and its main health-related responsibilities within the Korean government… The KFDA’s main duty is to cooperate and support with domestic and…
How would you rate South Korea’s healthcare system when compared to regional peers and other OECD countries – main strong points and room for improvement? Since the introduction of the…
You have a very long track record working with Novo Nordisk in Asia. What is your perspective on the Diabetes explosion that has been taking place in this part of…
Already an economic powerhouse thriving on export-driven industries such as electronics, automotive and ship-building, South Korea is now looking to boost its potential in the life sciences and to…
Over the last several years we have seen a shift in clinical research from traditional healthcare markets to Asia. How do you see this trend evolving in the coming years?…
See our Cookie Privacy Policy Here